Catheter Precision, Inc. VTAK

Competitive advantage analysis · healthcare

Medical Devices & Diagnostics
Overall moat score
44/100
Developing

Ranked against 159 peers in Medical Devices

About Catheter Precision, Inc.

Catheter Precision, Inc. designs, manufactures, and sells medical technologies for the field of cardiac electrophysiology (EP) in the United States. The company's lead product is View into Ventricular Onset System, a non-invasive imaging system that offers 3D cardiac mapping to help with localizing the sites of origin of idiopathic ventricular arrhythmias in patients with structurally normal hearts prior to EP … Full VTAK analysis →

Key strengths

  • Elite Gross Margins Gross margin quality is top-tier vs peers (score 0.98). This signals strong consumable attach-rate economics.
  • Improving FCF Trend FCF trend score is positive (score 0.98). Improving FCF margin signals compounding operational leverage.

Key risks

  • Weak Capital Return Profile Capital return quality is below peers (score 0.15). Low ROIC raises questions about M&A discipline and pipeline ROI.
  • Weak FCF Generation FCF margin quality lags peers (score 0.17). Below-peer FCF conversion is a MedTech quality warning.

The dashed ring is the peer median. Defense scores are percentile ranks against peers, so 50 is roughly the typical company in this group.

Upgrade to unlock the signals and evidence behind each defense.

Premium access

Unlock full defense analysis

Get key signals, strengths, and risks for every moat dimension.

Upgrade to Premium Unlock all moat defenses and evidence.

Pricing Power & Consumable Moat

Moderate
59
Premium

Signals, strengths and risks for Pricing Power & Consumable Moat

Premium

Signals, strengths and risks for R&D Pipeline & Capital Returns

Premium

Signals, strengths and risks for FCF Quality & Cash Conversion

Premium

Signals, strengths and risks for Commercial Execution

Premium

Signals, strengths and risks for Capital Structure & Resilience

Premium

Signals, strengths and risks for Growth Durability

Where VTAK ranks in Medical Devices

Catheter Precision, Inc. ranks #92 of 160 scored companies in Medical Devices by moat score — the top 57%. The widest moat in the group is iRadimed Corporation (IRMD) at 83/100.

# Company Moat score Rating
88 Sensus Healthcare, Inc. SRTS 46/100 Developing
89 Beta Bionics, Inc. BBNX 46/100 Developing
90 Pheton Holdings Ltd PTHL 45/100 Developing
91 IRIDEX Corporation IRIX 45/100 Developing
92 Catheter Precision, Inc. VTAK 44/100 Developing
93 MaxCyte, Inc. MXCT 44/100 Developing
94 Nuwellis, Inc. NUWE 44/100 Developing
95 Helius Medical Technologies, In HSDT 44/100 Developing
96 Trinity Biotech plc TRIB 44/100 Developing

See every Medical Devices & Diagnostics company ranked by moat score →

How VTAK scores on the Medical Devices & Diagnostics defenses

Pricing Power & Consumable Moat

Score 59 · 25% of the moat score

In MedTech, pricing power is rarely about the machine — it is about what the machine consumes.

R&D Pipeline & Capital Returns

Score 19 · 20% of the moat score

Research spending is how a device company keeps its installed base current, but spending alone proves nothing.

FCF Quality & Cash Conversion

Score 53 · 20% of the moat score

MedTech companies grow by acquisition, and the resulting intangible amortisation depresses reported earnings without consuming any cash.

Commercial Execution

Score 49 · 15% of the moat score

Devices are sold into hospitals and labs through committees, tenders and long qualification cycles, which makes the sales organisation expensive and hard to replicate.

Capital Structure & Resilience

Score 24 · 12% of the moat score

Serial acquirers carry debt, and the question is whether the cash flows underneath it are dependable enough to service it through a downturn.

Growth Durability

Score 62 · 8% of the moat score

Growth durability separates an expanding installed base from a good product cycle.

How each Medical Devices & Diagnostics defense is measured, in full →

Understanding VTAK's moat

What is Catheter Precision, Inc.'s moat score?

Catheter Precision, Inc. (VTAK) scores 44 out of 100 on the StatsAlpha Moat Map, which rates its competitive advantage as developing. It ranks #92 of 160 scored companies in Medical Devices, the top 57%. The score is a weighted composite of 6 competitive defenses, each measured against industry peers of 159 companies in Medical Devices. Its strongest defense is Growth Durability (62/100) and its weakest is R&D Pipeline & Capital Returns (19/100).

How does Catheter Precision, Inc. compare with other Medical Devices companies?

Catheter Precision, Inc. ranks #92 of 160 scored companies in Medical Devices by moat score. The widest moat in Medical Devices is iRadimed Corporation (IRMD) at 83/100. The companies ranked closest are IRIDEX Corporation (IRIX) at 45 just above it and MaxCyte, Inc. (MXCT) at 44 just below it.

How is the moat score calculated?

Each company is scored with an industry-specific template — Medical Devices & Diagnostics in this case, chosen because the defenses that matter to a bank are not the ones that matter to a software company. Every defense combines several financial signals, and each signal is measured as a percentile against a peer group of 159 companies in Medical Devices. The defenses are then weighted to produce the overall score out of 100.

Why is Catheter Precision, Inc. scored with the Medical Devices & Diagnostics template?

Medical device and diagnostics companies place an instrument once and then sell the consumables, reagents and service that instrument needs for the next decade. The economics are a razor-and-blade model wrapped in regulatory approval and clinician habit, so the MedTech template scores the durability of that installed base rather than the size of any single product launch.

Which competitive defenses are measured for Catheter Precision, Inc.?

The Medical Devices & Diagnostics template measures 6 defenses, and VTAK scores: Pricing Power & Consumable Moat (59), R&D Pipeline & Capital Returns (19), FCF Quality & Cash Conversion (53), Commercial Execution (49), Capital Structure & Resilience (24), Growth Durability (62). Each is scored independently as a percentile against peers, so a company can be strong on one and weak on another — the overall score reflects how those defenses are weighted for this industry.

Send Feedback
Please select a category.
0/1000